Cannabidiol dry powder inhalation (MannKind Corporation/Receptor Life Sciences)

大麻二酚干粉吸入剂 (MannKind Corporation/Receptor Life Sciences)

Report date: 2025/05/29 10:37:20

Base Information

Drug NameCannabidiol dry powder inhalation (MannKind Corporation/Receptor Life Sciences)
Drug Alias NameCBD Technosphere® Inhalation PowderRLS-103
ClassificationSmall molecules
Mechanisms of ActionCannabinoid CB2 receptor inverse agonistsCannabinoid CB1 receptor inverse agonistsSerotonin 5-HT1 receptors modulators +[4] 
TargetsCannabinoid CB2 receptorCannabinoid CB1 receptorSerotonin 5-HT1 receptors +[4] 
Therapy Area/IndicationsPhobia, SocialEpilepsy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMannKind CorpReceptor Life Sciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesReceptor Life Sciences Inc
Active IndicationsN/A
Inactive IndicationsPhobia, SocialEpilepsy

Other Information

ATC CodeN/A
Related LinksN/A